CEL-SCI Corp.
(NYSE Amex Equities : CVM)

( )
CVM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.48%171.281.3%$490.30m
BIIBBiogen Inc.
-0.90%227.061.3%$435.96m
CELGCelgene Corporation
-0.41%95.241.3%$435.38m
GILDGilead Sciences, Inc.
-0.42%66.890.9%$421.14m
ILMNIllumina, Inc.
1.13%312.453.5%$304.49m
REGNRegeneron Pharmaceuticals, Inc.
-0.86%312.562.6%$284.79m
AAgilent Technologies, Inc.
0.99%68.371.6%$218.10m
VRTXVertex Pharmaceuticals Incorporated
-0.72%171.771.9%$178.12m
EXASExact Sciences Corporation
3.06%96.8825.3%$165.46m
ALXNAlexion Pharmaceuticals, Inc.
1.45%127.152.0%$148.25m
BMRNBioMarin Pharmaceutical Inc.
2.42%89.074.3%$119.32m
INCYIncyte Corporation
1.55%81.752.5%$110.60m
SRPTSarepta Therapeutics, Inc.
2.19%120.8414.7%$106.75m
ALNYAlnylam Pharmaceuticals, Inc
1.50%68.939.2%$99.72m
IONSIonis Pharmaceuticals, Inc.
-3.60%64.728.2%$96.34m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.